RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br (Q85077949)
Jump to navigation
Jump to search
scientific article published on 11 October 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br |
scientific article published on 11 October 2011 |
Statements
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer (English)
Hope S Rugo
Adam M Brufsky
Sara Hurvitz
Raji Swamy
Vicente Valero
Vincent O'Neill
11 October 2011